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Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The frequency
of symptomatic central nervous system (CNS) involvement is unknown but thought to be a rare phenomenon.
Currently there are no known risk factors for CNS involvement.
Case presentation: We describe a clinically staged low-risk CLL case that presented with symptomatic CNS
involvement and progressed rapidly to death. Evaluation of the surface adhesion molecules identified a markedly
altered expression pattern of the integrin, CD49d, and the tetraspanin, CD82, in the index case when compared to
similar low-risk CLL cases. We found that the early Rai clinical stage CLL patients showed linear correlation for the
co-expression of CD82 and CD49d. In contrast, this unique index case with CNS involvement, which has the same Rai
clinical stage, had a significantly lower expression of CD82 and higher expression of CD49d.
Conclusions: These data suggest that the expression profile of CD49d and CD82 may represent potential biomarkers
for patients with increased propensity of CNS involvement. Moreover, this study illustrates the critical need for a better
mechanistic understanding of how specific adhesion proteins regulate the interactions between CLL cells and various
tissue sites.
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Chronic lymphocytic leukemia (CLL) is the most common
hematologic malignancy in Western countries. The hall-
mark of CLL is the progressive accumulation of CD5+ B
cells in the blood peripheral lymphoid organs, and bone
marrow [1]. In rare cases CLL can involve the central ner-
vous system (CNS). Recent systematic analysis data from
reported cases in the literature and a large case series of
over 4000 patients followed at a single institution have es-
timated a prevalence of symptomatic CNS involvement in
0.4% of patients with CLL, those findings are consistent
with other previously reported antemortem studies [2–4].* Correspondence: qtextian@hotmail.com
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involvement in up to 71% of patients with CLL [5]. To-
gether, these data imply that CLL infiltration of the CNS
is either underdiagnosed or frequently fails to manifest
clinically. However, for CLL patients with symptomatic
CNS involvement, the average time from diagnosis to
death is 12 months [6].
In general, CLL follows an extremely variable clinical
course with patient survival ranging from months to
decades [4]. Several pathological markers exist for CLL
diagnosis and prognosis, such as CD38 expression, im-
munoglobulin heavy chain variable region mutation status,
and FISH panels for specific genetic alterations [6]. How-
ever, thus far, studies have failed to identify risk factors that
effectively assist in early identification of CNS involvement
[6]. There has been no strong correlation with age, sex,le is distributed under the terms of the Creative Commons Attribution 4.0
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nophenotype, or peripheral white blood cell (WBC) counts
[5]. Initial studies reported that CNS infiltration occurs
more frequently in late stage CLL [7, 8]. However, a more
recent review of the literature indicates that one fourth of
all the published cases of CNS involvement were during
Rai stage 0 of CLL [6]. In fact recent data suggests that earl-
ier CLL stages are more likely to present with neurological
symptoms as the first signs of CLL, which is consistent with
the case we present in this study. While 48.8% of patients
with Rai stage 0-II disease presented with neurologic symp-
toms, only 10.7% of patients with stages III-IV disease pre-
sented with signs of neurologic involvement [6]. Therefore,
the timely diagnosis of CNS involvement and the identifica-
tion of risk factors for patients who develop CNS infiltra-
tion are crucial.
In combination, these data highlight the need for bio-
markers that can predict CNS involvement. Soluble
CD27 was a marker deemed useful at ruling out disease
with a negative predictive value of 92%; however it was
ultimately found to be highly non-specific with a positive
predictive value of 54% [9]. As such there remains a crit-
ical need to identify specific markers that can be used to
predict CNS involvement of CLL. We describe here a
case that based on all clinical criteria, was staged as a
low-risk CLL. Despite all of the low risk prognostic data,
the patient presented with CNS involvement and pro-
gressed rapidly. Evaluation of the surface adhesion mole-
cules on these CLL cells identified a unique differential
expression pattern of the integrin, CD49d, and tetraspa-
nin, CD82. Thus, analysis of the combined expression of
CD49d and CD82 may serve as a potential indicator of
CLL cells with propensity to involve the CNS.
Case presentation
A previously healthy 60 year old Caucasian female with
no significant past medical history was admitted to the
neurology service for progressive lower extremity weak-
ness and urinary incontinence. She endorsed fever fa-
tigue and a 20 pound weight loss over the preceding 3
to 4 months. Initially, the patient was presumptively
treated for Parkinson’s disease with carbidopa/levodopa
but had no improvement in symptoms. The patient de-
nied any preceding trauma or any family history of
neurological or hematological disease. The patient’s
exam demonstrated 3/5 strength in the hip flexors and
4/5 strength in the remainder exam, hyperreflexia in the
bilateral upper and lower extremities, and an otherwise
normal neurological exam. No lymphadenopathy or
splenomegaly was noted. A magnetic resonance imaging
(MRI) of the brain and spinal cord was consistent with
cord edema from C2 to T1 without evidence of a com-
pressive lesion. Spinal cord MRI demonstrated no acute
abnormalities (Fig. 1a). Serum antinuclear and anti-neutrophil cytoplasmic antibodies were not detected.
Examination of the cerebral spinal fluid (CSF) demon-
strated lymphocytosis (Fig. 1b). A comprehensive diag-
nostic investigation in the CSF and peripheral blood for
bacterial, fungal, viral cultures and cryptococcal antigen
did not reveal an infectious etiology. Oligoclonal band-
ing in the CSF was not suggestive of multiple sclerosis.
Additionally, flow cytometric analysis of the CSF (atrau-
matic and image-guided sample) and peripheral blood
revealed a monoclonal B cell population that expressed
CD19, dim CD20, dim surface light chain kappa, CD5,
CD23, and lack of FMC7 expression. This immunophe-
notype was consistent with CLL. The complete periph-
eral blood cell count showed a lymphocyte count of
13400/uL, hemoglobin of 13 gr/dL, and platelet count of
362 000/uL. Lactate dehydrogenase level was 188 U/L.
Staging imaging with CT of the chest, abdomen, and
pelvis did not demonstrate splenomegaly or lymphaden-
opathy. As such, the case was identified as clinical Rai
stage 0. The cytogenetics analysis by fluorescence in situ
hybridization was negative for deletion of chromosomes
11, 13, 17 or aneuploidy for chromosome 12, the im-
munoglobulin variable region (IGVH) revealed a hyper-
mutated status and the expression of CD38 was < 30% of
the CLL cells by flow cytometric analysis. A multidiscip-
linary evaluation of this case suggested that this patient’s
myriad of symptoms was the result of CLL with CNS in-
volvement. The patient was started on rituximab
375 mg/m2 IV in combination with cyclophosphamide
250 mg/m2 IV on days 1–3 plus fludarabine 25 mg/m2
IV on days 1–3. After the first cycle of chemotherapy
the patient exhibited improvement in the strength of the
hip flexors with stable strength in the rest of her physical
exam. No other new neurological abnormalities were
noted at that time. She transferred to her hometown to
establish care with a local oncologist. However, during
the subsequent 8 weeks her performance status declined
and the patient could not continue chemotherapy. She
was eventually transitioned to comfort-based care in a
hospice setting where her demise occurred.
Discussion
We studied this case, nested in a pilot institutional pro-
ject, evaluating the expression profile of specific adhe-
sion molecules that regulate critical interactions between
CLL cells and the microenvironment. Integrins, a family
of cell adhesion molecules, play a significant role in cell
motility, invasion and cell adhesion to the extracellular
matrix and supportive stromal cells. In the case of
CLL, the integrin CD49d or α4β1, has been linked to
migration of CLL cells across the vascular endothelium and
found to have clinical relevance for disease prognosis [10].
A recent study confirmed that patients with high CD49d
expression had significantly increased CLL infiltration of
Fig. 1 a T2 weighted sagittal cervical spine MRI evidencing segment enlargement and edema of the spinal cord extending from C2 to T1 levels
(arrows). b Cytospin preparation of the cerebral spinal fluid (magnification × 1000, Wright stain) reveals a cluster of chronic lymphocytic leukemic
cells with an admixed immunoblast (solid arrow) and a basophil (open arrowhead). c Correlation between CD82 and CD49d expression by mean
florescence intensity detected (MFI) using flow cytometry in Rai clinical stage 0 CLL patients in the pilot study: linear trendline (continuous line)
and 95% Confidence Interval (interrupted line). CNS case (red square) illustrated for comparison
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demonstrated that patients with CLL expressing CD49d
in ≥ 30% of neoplastic cells had a diminished 5 and 10-year
overall survival and treatment free survival [11]. These find-
ings were independent of CD38 and ZAP-70 expression. Fi-
nally, within a large-scale, worldwide, multicenter analysis,
CD49d emerged as the strongest flow cytometry-based pre-
dictor of overall survival and treatment-free survival [12].
Interestingly, previous microscopy studies identified
CD49d cellular localization within a protein complex
enriched on the plasma membrane of CLL cells [10]. Re-
cent work from our group established that CD49d pro-
tein organization and membrane density is regulated by
the tetraspanin scaffold protein, CD82, which signifi-
cantly impacts cell adhesion abilities [13]. Tetraspanins
facilitate the formation of membrane protein complexes
involved in multiple signaling pathways, tumor adhesion
and dissemination [14]. CD82 is the protein product of
the metastasis suppressor gene KAI1, which is located on
chromosome 11p11.2. Several studies have confirmed its
role as metastasis suppressor in many malignancies [15].
In patients with CLL, CD82 expression is upregulated
when compared with peripheral blood mononuclear cells
in normal controls. Moreover, a study evaluating geneexpression in molecular subgroups of CLL found that
CD82 was underexpressed in IGVH unmutated cases,
suggesting a role for CD82 in clinically aggressive CLL
[16]. However specific data on CD82 expression across
different disease stages has not yet been described.
In our pilot study, CLL cells from peripheral blood
were labeled in PAB buffer (PBS + 1% BSA + 0.02% so-
dium azide) for 30 min on ice with Alexa Fluor 647
CD82 (clone ASL-24; BioLegend) and Alexa Flour 488
integrin CD49d antibodies (clone 7.2R; R&D). Control
tubes of cells were labeled with isotype controls: Alexa
Flour 488 mouse IgG1 κ (clone 11711; R&D) and Alexa
Flour 647 mouse IgG1 κ (clone MOPC-21; BioLegend).
Cells were washed 3 times with PAB buffer and surface
fluorescence was measured using an Accuri C6 flow cyt-
ometer. Control tube fluorescence values were sub-
tracted from the experimental measurements to provide
the mean fluorescence values indicated.
Subsequently, we performed correlation studies between
the expression of CD49d and CD82 using a non-parametric
measure of statistical dependence (Spearman’s rank correl-
ation coefficient) to compare the mean fluorescence values
of CD49d and CD82 in CLL patients with early Rai clinical
stage, with a test significance level (P value) of 0.05. Our
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showed linear correlation for the co-expression of CD82
and CD49d (Fig. 1c, Spearman r = 0.71, P < 0.05). However,
in contrast, this unique index case with CNS involvement,
which had the same Rai clinical stage, had a significantly
lower expression of CD82 and higher expression of CD49d
(Fig. 1c, red square). The enhanced expression of CD49d is
consistent with poor patient prognosis in previous studies,
where CLL cells with high CD49d expression showed en-
hanced trafficking and adhesion to the bone marrow along
with increased cell survival [10–12]. Mechanistically, our
previous data suggest that CD82 is a crucial regulator of
CD49d membrane organization and molecular packing,
which in turn modulates the adhesive potential of CD49d
[13]. Therefore, the reduced expression of CD82 in thisTable 1 Demographic, clinical and prognostic characteristics of
early clinical stage CLL patients
Characteristics n = 14
Male
n (%) 11 (79)
Age (years)
Median (Min., Max.) 71 (60, 89)
Rai Clinical stage 0
n (%) 14 (100)
Absence of B symptomatology




Median (Min., Max.) 14.6 (10.0, 17.1)
Platelet count (X103 per microliter)
Median (Min., Max.) 171 (128, 257)
Lymphocyte count (X103 per microliter)
Median (Min., Max.) 12.2 (4.0, 58.2)
Overexpression of CD38
n (%) 3 (21)
Presence of IgVH hypermutation
n (%) 2 (14)
Cytogenetic abnormalities: n (%)
13q deletion 4 (29)
Trisomy 12 1 (7)
17p deletion 1 (7)
Follow-up duration from diagnosis (months)
Median (Min., Max.) 74.8 (32.5, 188.6)
Progression to treatment
n (%) 3 (21)
Time to progression from diagnosis (months)
Median (Min., Max.) 59.1 (11.4, 66.5)case may have disrupted the CD49d membrane packing or
density, which would affect cell adhesion and migration
abilities. We have shown that the membrane packing of
CD49d is independent of its surface expression as detected
by flow cytometric analysis. This shift in CD49d membrane
organization may explain the reduced cell adhesion and en-
hanced migratory behavior of the CLL cells, which led to
CNS invasion. Moreover, it is possible that the reduced
expression of CD82 resulted in a disruption of metastasis
suppression mechanisms, whereas the overexpression of
CD49d promoted the extravascular migration of CLL cells
to the CNS. Within our cohort of Rai stage 0 patients, the
two additional patients with increased CD49d expression
maintained indolent disease at the time of publication.
Taken together, these data suggest that high CD49d expres-
sion might be coupled with reduced CD82 expression for
enhanced predictive value.
Despite the favorable risk features in our patient mea-
sured by conventional clinical (Rai staging) immunophe-
notypic and cytogenetic criteria; she presented with CNS
involvement and neurologic symptoms. When compar-
ing the adhesion molecular profile of this patient to the
cohort of Rai stage 0 patients in our study we identified
an inverse relationship between the expression of
CD49d and CD82. With our current findings, we cannot
confirm whether the change in expression of CD49d and
CD82 in our case was a cause or an effect of CNS in-
volvement. However, we hypothesize that the reduction
of CD82 expression and the high level of CD49d may
contribute to the CNS involvement and the poor patient
outcome observed in this CLL case.
Conclusions
This case highlights the need for better predictive markers
in CLL, especially in atypical cases such as those with CNS
involvement. Our data suggest that the expression profile of
CD49d and CD82 may represent potential biomarkers in
predicting CNS involvement of CLL. Furthermore, this
study illustrates the critical need for a better mechanistic
understanding of how specific adhesion proteins regulate
the interactions between CLL cells and various tissue sites.
We anticipate that future large-scale studies will help to
elucidate dynamic changes in CD49d and CD82 expression
across different tissues, disease stages and over the course
of disease progression.
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